{
  "run_id": "753da7e1-9ebf-4cad-939b-c9a7eed8cbb8",
  "prompt_variant_id": "ef27e8e0-57d6-42b1-ab87-cbcdbb624a4f",
  "api_config_name": "model_deepseek_coder",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-09-03T17:20:11.153473",
  "end_time": "2025-09-03T17:20:13.918242",
  "duration_ms": 2746.3788986206055,
  "success": true,
  "error_message": "",
  "entities_extracted": 25,
  "entities_mapped": 25,
  "extraction_completeness": 1.5625,
  "mapping_accuracy": 0.5,
  "precision": 0.5555555555555556,
  "recall": 0.9375,
  "f1_score": 0.6976744186046512,
  "compliance_score": 1.0,
  "token_usage": 6336,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 0,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 25,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 11,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Histologically confirmed HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 30,
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 55,
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Measurable disease per RECIST 1.1",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 80,
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "RECIST 1.1",
      "type": "procedure",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 100,
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {
        "status": "positive",
        "value": "0-1",
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 115,
        "context_sentence": "ECOG performance status 0-1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Adequate organ function",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 140,
        "context_sentence": "Adequate organ function",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 165,
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Trastuzumab Deruxtecan",
      "type": "medication",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 185,
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 215,
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy or breastfeeding",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 240,
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-targeted therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": "20-40",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefSummary",
        "position": "60-73",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefSummary",
        "position": "74-96",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "progressed",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": "110-120",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "trastuzumab-based therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": "130-154",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefTitle",
        "position": "20-45",
        "context_sentence": "briefTitle: Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "30-65",
        "context_sentence": "officialTitle: A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefTitle",
        "position": "20-33",
        "context_sentence": "briefTitle: Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "30-43",
        "context_sentence": "officialTitle: A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Novel Therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "future"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefTitle",
        "position": "15-27",
        "context_sentence": "briefTitle: Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Novel Targeted Therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "future"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "officialTitle",
        "position": "20-42",
        "context_sentence": "officialTitle: A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Phase III",
      "type": "procedure",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "future"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "10-18",
        "context_sentence": "officialTitle: A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "Mcode_mappings": [
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "Direct mapping to cancer condition with HER2 biomarker status",
      "id": "32393e74-0039-42bf-90a4-6556fc9cb42b",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "Direct mapping to metastatic cancer condition",
      "id": "c102a095-99db-4edf-ac46-fb24c607617e",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "5b913800-e5f0-4630-bc01-1e24e4de5836",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 3",
      "mapping_rationale": "Combined cancer condition with biomarker and metastatic status",
      "id": "7b495568-f0bb-44c7-bedc-b88dd996b7e4",
      "llm_source_text_fragment": "Entity index 3",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 4",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "6404a46c-3202-45ab-8886-86fad67a23a3",
      "llm_source_text_fragment": "Entity index 4",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "Active disease",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 5",
      "mapping_rationale": "Measurable disease indicates active disease status",
      "id": "65b02631-4633-40de-a1ab-99c8e6f3b557",
      "llm_source_text_fragment": "Entity index 5",
      "source_references": []
    },
    {
      "resourceType": "Procedure",
      "Mcode_element": "CancerRelatedProcedure",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedprocedure",
        "display": "CancerRelatedProcedure"
      },
      "value": "RECIST 1.1 assessment",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 6",
      "mapping_rationale": "RECIST criteria used for tumor response assessment procedure",
      "id": "21b0829e-2201-42c7-896f-6cb0bac93366",
      "llm_source_text_fragment": "Entity index 6",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 7",
      "mapping_rationale": "Direct mapping to ECOG performance status score",
      "id": "5e0176c6-112b-4a15-b348-0fdc3cd0a53a",
      "llm_source_text_fragment": "Entity index 7",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Adequate organ function",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 8",
      "mapping_rationale": "General condition requirement for treatment eligibility",
      "id": "b6d4b521-4283-492b-926a-52d768631381",
      "llm_source_text_fragment": "Entity index 8",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 9",
      "mapping_rationale": "Cancer medication with exclusion status (negative)",
      "id": "562daed4-924a-4718-bddc-51039a991d1c",
      "llm_source_text_fragment": "Entity index 9",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 10",
      "mapping_rationale": "Direct mapping to cancer medication",
      "id": "b37bb434-728f-498f-9710-fca178b7d728",
      "llm_source_text_fragment": "Entity index 10",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Brain metastases",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 11",
      "mapping_rationale": "Metastatic cancer condition with exclusion status (negative)",
      "id": "cf43a420-50a2-4355-8e7b-8737944f37e9",
      "llm_source_text_fragment": "Entity index 11",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Pregnancy or breastfeeding",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 12",
      "mapping_rationale": "General medical condition with exclusion status",
      "id": "028d0ade-51a5-4ca7-9bb4-faa1117cacef",
      "llm_source_text_fragment": "Entity index 12",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "HER2-targeted therapy",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 13",
      "mapping_rationale": "General class of cancer medications targeting HER2",
      "id": "827ec1b1-3a09-4e02-a13e-e5aa064507a6",
      "llm_source_text_fragment": "Entity index 13",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 14",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "9ecc5c28-2ab9-45d8-8383-e565627c80bb",
      "llm_source_text_fragment": "Entity index 14",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 15",
      "mapping_rationale": "Direct mapping to metastatic cancer condition",
      "id": "3a186001-ba45-44cc-9891-13a8d7254d04",
      "llm_source_text_fragment": "Entity index 15",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "Progressive disease",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 16",
      "mapping_rationale": "Progressed indicates disease progression status",
      "id": "af988280-8c57-485b-91f3-8102251a5179",
      "llm_source_text_fragment": "Entity index 16",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab-based therapy",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 17",
      "mapping_rationale": "Cancer medication class including trastuzumab",
      "id": "0614ab02-babe-4fe8-b51a-088b46b9accc",
      "llm_source_text_fragment": "Entity index 17",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 18",
      "mapping_rationale": "Direct mapping to cancer condition with biomarker",
      "id": "fbda7bcd-50d5-4a3c-af38-a31e7ea2c3a5",
      "llm_source_text_fragment": "Entity index 18",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 19",
      "mapping_rationale": "Combined cancer condition with biomarker and metastatic status",
      "id": "4aea6633-749c-4a2e-a66e-86868a3f1ffd",
      "llm_source_text_fragment": "Entity index 19",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 20",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "224763e6-6c4a-4fca-8ff7-765af8f9c3bd",
      "llm_source_text_fragment": "Entity index 20",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 21",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "3251d058-83db-4b1b-9351-c477dfe26fd1",
      "llm_source_text_fragment": "Entity index 21",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Novel Therapy",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 22",
      "mapping_rationale": "General cancer medication description",
      "id": "85168c75-2a23-4d7a-aad0-0d1e18954c56",
      "llm_source_text_fragment": "Entity index 22",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Novel Targeted Therapy",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 23",
      "mapping_rationale": "Targeted cancer medication description",
      "id": "e4134ae2-c005-475d-9af7-cdf9a71edc8e",
      "llm_source_text_fragment": "Entity index 23",
      "source_references": []
    },
    {
      "resourceType": "Procedure",
      "Mcode_element": "CancerRelatedProcedure",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedprocedure",
        "display": "CancerRelatedProcedure"
      },
      "value": "Phase III clinical trial",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 24",
      "mapping_rationale": "Clinical trial phase maps to cancer-related procedure",
      "id": "cd9a3f2a-0823-46be-a779-0a5d4732c1ff",
      "llm_source_text_fragment": "Entity index 24",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}